Professor Mark Middleton

Professor Mark Middleton is Professor of Experimental Cancer Medicine and a Consultant Medical Oncologist. Professor Middleton studied medicine at Cambridge and Oxford. He also trained in medical oncology at the Christie Hospital. Professor Middleton has overseen the development of internationally leading melanoma and upper GI clinical research groups. He has also overseen the establishment of portfolios of early-phase radiotherapy and haematooncology trials in Oxford. Professor Middleton is involved in evaluating novel immunotherapeutics, including pre-clinical development, trial design, proof of mechanism and proof of concept. One of his major research goals is to better understand why not all patients benefit from the new drugs available to treat melanoma. Genetic characteristics or signatures are being explored to identify patients who are likely to benefit from particular treatments and to make informed treatment decisions on the best combinations of drugs to use in the clinic.